CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
ADmit Therapeutics is developing the MAP-AD platform, which uses machine learning to analyze blood samples for predicting the progression of prodromal Alzheimer's disease. This innovative diagnostic tool aims to improve patient selection for clinical trials, enhancing the efficiency of drug development.
Each year an estimated 40M people suffer from Alzheimer’s disease (AD) globally, and a new case is diagnosed every 4 seconds, leading to a substantial socioeconomic burden of over €800B annually.
Despite this large need, currently there is no cure available for AD.
Moreover, the clinical trial failure rate for novel AD therapies being tested is over 99%.
Every failed trial leads to large financial losses for the trial sponsor, and as a result there is an urgent need to reimagine AD clinical tria…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
